在市场规模微增、新能源替代加速、消费需求升级及国际竞争加剧的行业背景下，中国商用车 市场正加速洗牌。2025年上半年，上汽大通MAXUS以"爆品驱动销量"，6月热销19,954 辆、同比激增31％。半年累计销量达107,467辆、同比增长11.2%，新能源车型同比增长 69%。跃进轻卡系列6月销量同比大增132.9%，上半年同比增长89.1%，以强劲增速领跑城 配物流市场；"创富神车"大拿成为商用车新能源转型的标杆爆品，进一步夯实上汽大通"中国 轻客第一品牌"的市场地位。 跃进轻卡在新能源化转型的道路上"一路跃进"。以"用户需求导向＋技术驱动创新"发展模 式，全面深化产业协同。跃进轻卡抢抓新能源赛道商机，构建规模化、高品质、更节能的电动 轻卡生态，实现6月销量翻番，同比大增125.2%，带动上半年同比增长63.1%，成为城配物 流市场黑马。 全品类协同增长，单日交付创新高。上半年，上汽大通在各个细分市场，展现强劲势头。4月 成为皮卡圈环比增长最快的品牌，5月成为轻客市场唯一同环比双增的品牌，6月，上汽大通 单日交付量与大拿单日交付量双双创新高，保持良好增长态势。"全球唯一10 万级混动 MPV"G50混动领衔 ...

白交 发自 凹非寺 量子位 | 公众号 QbitAI 国产GPU第一股要来了？！ 最新消息， 摩尔线程 完成上市辅导。 官网显示，摩尔线程智能科技（北京）股份有限公司IPO辅导状态已变更为"辅导验收"，辅导机构为中信证券股份有限公司。 这个创始团队来自英伟达，创始人兼CEO张建中在GPU这一行业已经深耕近二十年。 从2020年诞生以来，这家公司就颇受资本市场关注，实现过「百天长成独角兽」的战绩。去年11月正式启动上市进程时，企业估值达到了 255亿元。 目前已累计完成6轮融资，融资总金额超过45亿元。今年2月份还获得了一份来自高粱基金的战略投资，不过具体金额没有披露。 投资方阵容包括了红杉中国、腾讯、字节、小马智行这些知名投资机构和企业，可以说是非常豪华了。 此消息一出，多只摩尔线程概念股上涨，比如和而泰盘中涨超8%。 国产GPU第一股 摩尔线程成立于2020年6月，注册资本3.3亿元。实控人为张建中，控制公司44.07%股份。 | 辅 导对象 | 摩尔线程智能科技(北京)股份有限公司 | | | | --- | --- | --- | --- | | 成立日期 | 2020年6月11日 | | | | 注 ...

Core Viewpoint - Company is undergoing an innovative transformation, focusing on chronic diseases, tumors, and immunology, with multiple products entering a harvest phase, maintaining a "buy" rating [1] Group 1: Business Segments - Company covers four major business segments: pharmaceutical manufacturing, pharmaceutical commerce, medical aesthetics, and industrial microbiology, optimizing product structure towards innovation [1] - Pharmaceutical manufacturing revenue is projected to reach 138.1 billion yuan in 2024, reflecting a year-on-year growth of 13.1% [2] - Medical aesthetics revenue is expected to recover gradually as new products are launched, despite a current decline of 4.9% [2] Group 2: Financial Performance - Company forecasts 2024 revenue of 419.1 billion yuan, a year-on-year increase of 3.2%, with a net profit of 35.1 billion yuan, up 23.7% [2] - Expected net profits for 2025, 2026, and 2027 are 40.61 billion yuan, 47.16 billion yuan, and 55.37 billion yuan respectively, with corresponding EPS of 2.32, 2.69, and 3.16 yuan [1] Group 3: Innovation Pipeline - Company is focusing on differentiated layouts in ADC and PROTAC technologies, with several products entering clinical stages [3] - The pipeline includes oral small molecule drugs for diabetes and obesity, with significant milestones expected in 2025 [3] Group 4: Market Sentiment - Recent ratings show 16 out of 17 institutions recommend a "buy" rating, with an average target price of 49.22 yuan [4]

● 本报记者齐金钊 日前，世界无人机大会在深圳举行。来自无人机产业领域的专家学者及产业链人士，围绕无人机与低空 经济、低空数字交通、低空飞行服务、低空基础设施与管理平台等主题，进行了深入探讨交流，共同解 码低空经济发展的最新趋势。 无人机应用范围广 从商业化试运营的载人低空飞行器，到超长航时的工业级无人机，再到涵盖无人机全产业链的软硬件产 品……记者在大会现场了解到，本届世界无人机大会吸引了国内外超800家优质低空企业，携5000多款 无人机系统装备新产品进行展示。 随着无人机应用范围的持续拓展，全产业链正呈现出蓬勃发展的势头。以深圳为例，据官方统计数据， 深圳目前拥有无人机相关上中下游全产业链，整机制造及链上企业达2000多家，产值超过1000亿元。今 年一季度，深圳民用无人机产量同比增长48.2%，正成为经济发展的一个新增长点。 业内人士表示，无人机已成为驱动低空经济发展的新引擎。大力促进低空经济发展，不仅有利于拓展市 场空间，更是推动高质量发展的内在需求。低空经济既承续了传统通用航空业态，又融合了以无人机为 支撑的新型低空生产服务方式，依赖信息化、数字化管理技术赋能，形成了一种容纳并推动多领域协调 发展 ...

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView has published an exclusive interview with Alexandre Mongeon, CEO and Co-Founder of Vision Marine Technologies (Nasdaq: VMAR), a company at the forefront of electric marine propulsion. Vision Marine is leading the transformation of recreational boating through fully integrated electric propulsion systems, commercial-ready vessels, and strategic partnerships with manufacturers. Alexandre Mongeon, CEO and Co-Founder of Vision Marine Technologies In t ...

证券代码：000963 证券简称：华东医药 华东医药股份有限公司投资者关系活动记录表 12.29%，环比2024年第四季度增长24.37%，整体经营符合第一季度计 划目标。国内医美全资子公司欣可丽美学积极拓展国内市场，报告期 内实现营业收入2.54亿元，同比下降1.36%，环比2024年第四季度增长 10.64% 。公司持续深化国内高端医美产品布局，高端玻尿酸 MaiLi®Extreme（商品名：魅俪®朔盈®）将于2025年5月正式实现商业化 销售；多功能面部皮肤管理平台Préime DermaFacial也将于2025年内正 式实现商业化销售。此外，重组A型肉毒毒素YY001、能量源设备V30 及Ellansé®伊妍仕®M型等核心医美产品国内上市申请均已获受理，有 望于2026年获批。依托国内差异化医美产品矩阵的持续丰富，叠加消 费升级带来的市场需求扩容，公司国内医美业务成长潜能将加速释放。 编号：2025-002 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系 | □业绩说明会 □媒体采访 | | 活动类别 | □新闻发布会 □路演活动 | | | □现场参观 ☑其他 ...

Financial Performance - In 2024, the company achieved a revenue of CNY 41.906 billion, a year-on-year increase of 3.16% [4] - The net profit attributable to shareholders was CNY 3.512 billion, up 23.72% year-on-year [4] - The net profit after deducting non-recurring gains and losses was CNY 3.352 billion, reflecting a growth of 22.48% [4] - Compared to 2021, revenue and net profit grew by 21.24% and 52.59%, respectively [4] Business Segments Performance Pharmaceutical Industry - The pharmaceutical segment generated a revenue of CNY 13.811 billion, with a year-on-year growth of 13.05% [5] - The net profit for this segment was CNY 2.876 billion, increasing by 29.04% [5] - R&D investment in the pharmaceutical industry reached CNY 2.678 billion, a 16.77% increase [5] Aesthetic Medicine - The domestic aesthetic medicine subsidiary reported a revenue of CNY 1.139 billion, growing by 8.32% [6] - The UK subsidiary, Sinclair, generated approximately CNY 0.967 billion, a decline of 25.81% due to global economic challenges [6] Industrial Microbiology - The industrial microbiology segment achieved a revenue of CNY 0.711 billion, a significant increase of 43.12% [25] - Growth rates for specific areas included 38% for specialty raw materials and intermediates, 20% for xRNA, and 142% for health and biological materials [25] R&D and Product Development - The company has over 80 innovative drug candidates in its pipeline [5] - The oral small molecule GLP-1 receptor agonist HDM1002 has shown promising results in clinical trials, with over 800 participants [17] - The ADC pipeline includes more than 12 projects, with ongoing clinical trials for several candidates [14] Market Strategy and Future Outlook - The company plans to actively participate in medical insurance negotiations for new products [6] - There is a focus on expanding market presence in both domestic and international markets, particularly in the aesthetic medicine sector [26] - The company anticipates a gradual recovery in overseas aesthetic medicine markets [26] Investor Relations and Communication - The annual performance meeting was attended by 381 institutional and individual investors [2] - The chairman emphasized the commitment to high-quality development and strategic goals for the upcoming three-year plan [27]